Janssen hasn’t released Phase III data yet but says the next-generation androgen receptor inhibitor showed potential benefit for metastasis-free survival.
Janssen Biotech Inc. hopes it will be first to market with a drug for non-metastatic castration-resistant prostate cancer (CRPC) with the submission of its next-generation androgen receptor inhibitor apalutamide, based on a Phase III study providing data on metastasis-free survival.
Apalutamide will be positioned in tandem with Janssen’s blockbuster prostate cancer therapy Zytiga (abiraterone acetate). "Prostate cancer is an area...
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
